Sensorion, a clinical-stage biotech company focused on hearing loss therapies, is participating in the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting on May 11-15, 2026, in Boston, USA.1
Laurent Desire, Head of Preclinical Development, will present a poster on 'Safety, biodistribution and efficacy of SENS-601, an AAV-based gene therapy for DFNB1A deafness' on May 12, 2026, 5-6:
30 pm ET.1
Marina Dos Santos, DSP Manager, will present a poster on 'Development and scale-up of an enrichment step for a difficult-to-produce recombinant AAV serotype' on May 12, 2026, 5-6:
30 pm ET.1
SENS-601 targets GJB2 gene mutations for hereditary deafness in adults and children, part of collaboration with Institut Pasteur.1
Sources:
1. https://www.biospace.com/press-releases/sensorion-announces-its-participation-in-the-american-society-of-gene-cell-therapy-asgct-annual-meeting